

Ref: FOIA Reference 2020/21-505

Royal Stoke University Hospital  
Data, Security and Protection  
Newcastle Road  
Stoke-on-Trent  
Staffordshire  
ST4 6QG

Date: 26<sup>th</sup> February 2021

Email [foi@uhnm.nhs.uk](mailto:foi@uhnm.nhs.uk)

Dear

I am writing in response to your email dated 5<sup>th</sup> February 2021 requesting information under the Freedom of Information Act (2000) regarding antiretroviral therapies.

As of 1<sup>st</sup> November 2014 University Hospitals of North Midlands NHS Trust (UHM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

**Q1 I am analysing the usage of antiretroviral therapies. Could you please answer the following four questions?**

**Q1 How many patients were treated (for any condition) in the latest 6-month period with the following drugs:**

- Juluca (rilpivirine/dolutegravir)
- Dovato (lamivudine/dolutegravir)
- Triumeq (abacavir/lamivudine/dolutegravir)
- Tivicay (dolutegravir)
- Isentress (raltegravir)
- Biktarvy (TAF/emtricitabine/bictegravir)
- Genvoya (TAF/emtricitabine/elvitegravir/cobisistat)
- Symtuza (TAF/emtricitabine/darunavir/cobisistat)
- Odefsey (TAF/emtricitabine/rilpivirine)
- Descovy (TAF/emtricitabine)
- Truvada or generic TDF/emtricitabine

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed. Please see below:

- Juluca (rilpivirine/dolutegravir): 0
- Dovato (lamivudine/dolutegravir): 0

- Triumeq (abacavir/lamivudine/dolutegravir): 0
- Tivicay (dolutegravir): 6
- Isentress (raltegravir): 5
- Biktarvy (TAF/emtricitabine/bictegravir): 0
- Genvoya (TAF/emtricitabine/elvitegravir/cobisistat): 0
- Symtuza (TAF/emtricitabine/darunavir/cobisistat): <5
- Odefsey (TAF/emtricitabine/rilpivirine): 0
- Descovy (TAF/emtricitabine): <5
- Truvada or generic TDF/emtricitabine: 7

**Q2 How many patients received any antiretroviral (ART) therapy for HIV treatment (excluding pre- exposure prophylaxis):**

- **for the latest 6-month period**
- **for the 6 months from July-December 2019**

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <20

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed. Please see below:

- For the latest 6-month period: <20 patients
- For the 6 months from July-December 2019: <20 patients

**Q3 How many patients were treated in the latest 6-months period with Truvada or generic TDF/emtricitabine for?**

- **HIV treatment**
- **Pre-exposure prophylaxis (PrEP)**

A3 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5 and <10

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed. Please see below:

- HIV treatment: <10 patients
- Pre-exposure prophylaxis (PrEP) : <5 patients

**Q4 How many packs of Truvada or generic TDF/emtricitabine were dispensed in latest 6-month period for?**

- **HIV treatment**
- **Pre-exposure prophylaxis (PrEP)**

A4 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5 and <10

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed. Please see below:

- HIV treatment: <10 packs
- Pre-exposure prophylaxis (PrEP): <5 packs

\*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

***UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.***

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.


Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via [www.ico.org.uk](http://www.ico.org.uk).

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,

A handwritten signature in black ink on a light-colored background. The signature reads "Jean Lehnert" in a cursive script.

Jean Lehnert  
**Data, Security & Protection Manager**